AMENDMENTS TO THE CLAIMS

- 1. (Original) An HLA-E chimeric molecule possessing the following amino acid sequence:
- (1) HLA-E chimeric molecule replacing all or part of $\alpha 2$ domain of HLA-E molecule with all or part of $\alpha 2$ domain of HLA-G1 molecule,
- (2) HLA-E chimeric molecule replacing, together with (1), signal peptide (SP) of HLA-E molecule with reformed SP partly reforming the SP of HLA-G1 molecule, or
- (3) HLA-E chimeric molecule replacing, together with (2), a part of amino acid sequence of α1 domain and α2 domain of HLA-E molecule, with a part of amino acid sequence of α1 domain and α2 domain of HLA-G1 molecule, respectively.
- 2. (Original) A base sequence for coding any HLA-E chimeric molecule of claim 1.
- (Original) A nonhuman mammal cell or nonhuman mammal animal transformed by the base sequence of claim 2.
- 4. (New) The HLA-E chimeric molecule of claim 1, wherein the SP of HLA-E molecule is replaced with the reformed SP, and serine of amino acid number 147 of $\alpha 2$ domain of HLA-E molecule is replaced with cysteine of amino acid number 147 of $\alpha 2$ domain of HLA-G1 molecule.
- 5. (New) The HLA-E chimeric molecule of claim 1, wherein the SP of HLA-E molecule is replaced with the reformed SP, and serine of amino acid number 11 of αl domain of HLA-E molecule and serine of amino acid number 147 of α2 domain of the same are replaced with alanine of amino acid number 11 of αl of HLA-G1 molecule and cysteine of amino acid number 147 of α2 of the same, respectively.

Docket No.: 2520-0132PUS1

Page 2 of 5